Gujarat Kidney IPO Launch: ₹114 Price Band Set for ₹250 Cr Healthcare Float – Will This Be the Next Big Healthcare Gem?
Overview
Gujarat Kidney and Super Speciality Limited is launching its Initial Public Offering (IPO) with a price band of ₹108 to ₹114 per share. The healthcare provider aims to raise ₹250.80 crore through this issue, which opens on December 22 and closes on December 24, 2025. Proceeds will fund expansion, acquisitions like Parekhs Hospital, capital expenditure for new facilities, and debt repayment, bolstering its balance sheet and supporting inorganic growth.
The Core Issue
Gujarat Kidney and Super Speciality Limited, a prominent healthcare provider in central Gujarat, has announced its intention to go public. The company unveiled a price band of ₹108 to ₹114 per share for its upcoming Initial Public Offering (IPO). This move aims to raise a substantial ₹250.80 crore to fuel its growth and operational enhancements.
The IPO is scheduled to open for subscription on December 22, 2025, and will conclude on December 24, 2025. The allotment of shares is expected on December 26, with the company's shares slated to begin trading on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on December 30, 2025. This public offering represents a significant milestone for the regional healthcare player.
Financial Highlights
Gujarat Kidney has demonstrated robust financial performance in the recently concluded fiscal year. For the financial year ended March 31, 2025, the company reported a significant jump in total income, reaching ₹40.40 crore, a substantial increase from ₹5.48 crore in the previous year. Profit after tax (PAT) also saw a dramatic rise to ₹9.50 crore, up from ₹1.71 crore in FY24.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) experienced a sharp escalation, growing to ₹16.55 crore in FY25 from ₹1.95 crore in FY24. This strong profitability surge is reflected in its strengthened net worth, which stood at ₹25.71 crore as of March 31, 2025, a considerable improvement from ₹10.80 crore a year prior. The company's financial health appears solid, supported by modest borrowings of ₹4.03 crore as of June 30, 2025.
Fund Utilization
The net proceeds generated from the IPO are earmarked for several strategic initiatives aimed at enhancing the company's footprint and financial stability. A significant allocation of ₹77 crore is designated for the acquisition of Parekhs Hospital in Ahmedabad, marking a key step in its expansion strategy.
Further investment includes ₹12.40 crore for part-payment of the purchase consideration for the already acquired Ashwini Medical Centre. The company also plans to invest ₹30.10 crore in capital expenditure for establishing a new hospital in Vadodara. An additional ₹6.83 crore will be used to procure advanced robotics equipment for its Gujarat Kidney & Super Speciality Hospital in Vadodara.
A smaller sum of ₹1.20 crore is set aside for the repayment or prepayment of outstanding secured borrowings. The remaining funds will be strategically deployed to support unidentified future acquisitions, cover general corporate needs, and increase shareholding in its subsidiary, Harmony Medicare Private Limited.
Future Outlook
The company's financial trajectory continues to show positive momentum into the current fiscal year. For the quarter ended June 30, 2025, Gujarat Kidney reported a PAT of ₹5.40 crore on total income of ₹15.27 crore. Total assets have seen considerable growth, standing at ₹61.59 crore as of June 30, 2025, compared to ₹20.53 crore a year earlier.
The IPO proceeds are expected to significantly bolster the company's expansion plans, enabling acquisitions and strengthening its balance sheet. This strategic deployment of capital positions Gujarat Kidney and Super Speciality Limited for continued growth in the competitive Indian healthcare sector. Investors will be watching closely as the company navigates its public debut and execution of its expansion strategy.
Impact
This IPO is expected to have a positive impact on the Indian healthcare sector, particularly in central Gujarat, by bringing in capital for expansion and potentially improving healthcare access. For investors, it offers an opportunity to invest in a growing regional healthcare provider.
Impact Rating: 7/10
Difficult Terms Explained
Initial Public Offering (IPO): The first time a private company offers its shares to the public.
Price Band: A range within which the price of a share will be fixed during the IPO.
Qualified Institutional Buyers (QIBs): Large institutional investors like mutual funds, foreign institutional investors, etc.
Retail Investors: Individual investors who apply for shares up to a certain limit.
Non-Institutional Investors (NIIs): High-net-worth individuals and corporate bodies not categorized as QIBs.
Profit After Tax (PAT): The profit remaining after all expenses, including taxes, have been deducted.
EBITDA: A measure of a company's operating performance before accounting for interest, taxes, depreciation, and amortization.
Net Worth: The total assets minus total liabilities, representing the owners' equity in the company.
Capital Expenditure: Funds used by a company to acquire, upgrade, and maintain physical assets like property or equipment.
Inorganic Growth: Expansion through the acquisition of other companies rather than through internal growth.
